Inconsistent immunohistochemical expression patterns of four different cd133 antibody clones in glioblastoma

Journal of Histochemistry and Cytochemistry

Volumn 59, Issue 4, 2011, Pages 391-407

  Hermansen, Simon K ^a   Christensen, Karina G ^a   Jensen, Stine S ^a   Kristensen, Bjarne W ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Antibodies; CD133; Comparative; Glioblastoma; Immunohistochemistry; Niche; Quantitative; Stem cell; Stereology

Indexed keywords

CD133 ANTIGEN; ANTIBODY; EPITOPE; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL CULTURE; CELL STRUCTURE; CLINICAL ARTICLE; CLONE; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY PARENCHYMA; MALE; PANCREAS; PLACENTA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RETINOBLASTOMA; SINGLE CELL ANALYSIS; STEREOLOGY; ANTIBODY SPECIFICITY; BIOSYNTHESIS; BRAIN TUMOR; CANCER STEM CELL; COMPARATIVE STUDY; GLYCOSYLATION; IMMUNOLOGY; KIDNEY; METABOLISM; MIDDLE AGED; PREGNANCY; TUMOR CELL CULTURE; VASCULARIZATION;

ADULT; AGED; ANTIBODIES; ANTIGENS, CD; BRAIN NEOPLASMS; EPITOPES; FEMALE; GLIOBLASTOMA; GLYCOPROTEINS; GLYCOSYLATION; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; MIDDLE AGED; NEOPLASTIC STEM CELLS; ORGAN SPECIFICITY; PANCREAS; PEPTIDES; PLACENTA; PREGNANCY; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 79955676408     PISSN: 00221554     EISSN: None     Source Type: Journal    
DOI: 10.1369/0022155411400867     Document Type: Article

References (58)

1. Al-Hajj M, Wicha MS, Ito-Hernandez A, Morrison SJ, Clarke MF. 2003. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 100:3983-3988.
2. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP. 2007. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res. 67:4010-4015.
3. Beier D, Wischhusen J, Dietmaier W, Hau P, Proescholdt M, Brawanski A, Bogdahn U, Beier CP. 2008. CD133 expression and cancer stem cells predict prognosis in high-grade oligodendroglial tumors. Brain Pathol. 18:370-377.
4. Bidlingmaier S, Zhu X, Liu B. 2008. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells. J Mol Med. 86:1025-1032.
5. Brehar FM, Bleotu C, Stefan LM, Buzgariu W, Chivu M, Utoiu E, Matei L, Ciurea AV, Tascu A. 2009. Isolation and partial characterization of a new human glioblastoma cell line. Chirurgia. 104:453-461.
6. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, Hamner B, Oh EY, Gaber MW, Finklestein D, Allen M, et al. 2007. A perivascular niche for brain tumor stem cells. Cancer Cell. 11:69-82.
7. Christensen K, Aaberg-Jessen C, Andersen C, Goplen D, Bjerkvig R, Kristensen BW. 2010. Immunohistochemical expression of stem cell, endothelial cell, and chemosensitivity markers in primary glioma spheroids cultured in serum-containing and serum-free medium. Neurosurgery. 66:933-947.
8. Christensen K, Schrøder HD, Kristensen BW. 2008. CD133 identifies perivascular niches in grade II-IV astrocytomas. J Neurooncol. 90:157-170.
9. Clément V, Dutoit V, Marino D, Dietrich PY, Radovanovic I. 2009. Limits of CD133 as a marker of glioma self-renewing cells. Int J Cancer. 125:244-248.
10. Clément V, Marino D, Cudalbu C, Hamou MF, de Mlynarik VTN, Dietrich PY, Gruetter R, Hegi ME, Radovanovic I. 2010. Marker-independent identification of glioma-initiating cells. Nat Methods. 7:224-228.
11. Corbeil D, Roper K, Fargeas CA, Joester A, Huttner WB. 2001. Prominin: a story of cholesterol, plasma membrane protrusions and human pathology. Traffic. 2:82-91.
12. Corbeil D, Roper K, Hellwig A, Tavian M, Miraglia S, Watt SM, Simmons PJ, Peault B, Buck DW, Huttner WB. 2000. The human AC133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. J Biol Chem. 275:5512-5520.
13. Fargeas CA, Huttner WB, Corbeil D. 2007. Nomenclature of prominin-1 (CD133) splice variants: an update. Tissue Antigens. 69:602-606.
14. Fargeas CA, Joester A, Missol-Kolka E, Hellwig A, Huttner WB, Corbeil D. 2004. Identification of novel prominin-1/CD133 splice variants with alternative C-termini and their expression in epididymis and testis. J Cell Sci. 117(Pt 18):4301-4311.
15. Florek M, Haase M, Marzesco AM, Freund D, Ehninger G, Huttner WB, Corbeil D. 2005. Prominin-1/CD133, a neural and hematopoietic stem cell marker, is expressed in adult human differentiated cells and certain types of kidney cancer. Cell Tissue Res. 319:15-26.
16. Gilbertson RJ, Rich JN. 2007. Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer. 7:733-736.
17. Gundersen HJ. 1986. Stereology of arbitrary particles: a review of unbiased number and size estimators and the presentation of some new ones, in memory of William R. Thompson. J Microsc. 143(Pt 1):3-45.
18. Gundersen HJ. 1992. Stereology: the fast lane between neuroanatomy and brain function-or still only a tightrope? Acta Neurol Scand Suppl. 137:8-13.
19. Gundersen HJ, Bendtsen TF, Korbo L, Marcussen N, Moller A, Nielsen K, Nyengaard JR, Pakkenberg B, Sorensen FB, Vesterby A. 1988. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis, APMIS. 96:379-394.
20. Gundersen HJ, Jensen EB. 1987. The efficiency of systematic sampling in stereology and its prediction. J Microsc. 147(Pt 3):229-263.
21. Gunther HS, Schmidt NO, Phillips HS, Kemming D, Kharbanda S, Soriano R, Modrusan Z, Meissner H, Westphal M, Lamszus K. 2008. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene. 27:2897-2909.
22. Hermann PC, Huber SL, Herrler T, Aicher A, Ellwart JW, Guba M, Bruns CJ, Heeschen C. 2007. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell. 1:313-323.
23. Immervoll H, Hoem D, Sakariassen PO, Steffensen OJ, Molven A. 2008. Expression of the stem cell marker CD133 in pancreas and pancreatic ductal adenocarcinomas. BMC Cancer. 8:48.
24. Jaszai J, Fargeas CA, Florek M, Huttner WB, Corbeil D. 2007. Focus on molecules: prominin-1 (CD133). Exp Eye Res. 85:585-586.
25. Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, et al. 2008. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest. 88:808-815.
26. Kemper K, Sprick MR, de Scopelliti BMA, Vermeulen L, Hoek M, Zeilstra J, Pals ST, Mehmet H, Stassi G, Medema JP. 2010. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res. 70:719-729.
27. Kolenda J, Jensen SS, Aaberg-Jessen C, Christensen K, Andersen C, Brunner N, Kristensen BW. 2010. Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J Neurooncol. Sep 11. [Epub ahead of print]
28. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, et al. 2006. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 9:391-403.
29. Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, Wicha M, Clarke MF, Simeone DM. 2007. Identification of pancreatic cancer stem cells. Cancer Res. 67:1030-1037.
30. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. 2007. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 114:97-109.
31. Maitland NJ, Collins AT. 2008. Prostate cancer stem cells: a new target for therapy. J Clin Oncol. 26:2862-2870.
32. Malhotra V, Malik R, Gondal R, Beohar PC, Parkash B. 1986. Evaluation of histological appearance of tissues removed by cavitron ultrasonic surgical aspirator (CUSA). Acta Neurochir (Wien). 81(3-4):132-134.
33. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT, Bray RA, Waller EK, Buck DW. 1997. A novel fivetransmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning. Blood. 90:5013-5021.
34. Mizrak D, Brittan M, Alison MR. 2008. CD133: molecule of the moment. J Pathol. 214:3-9.
35. O'Brien CA, Pollett A, Gallinger S, Dick JE. 2007. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 445:106-110.
36. Osmond TL, Broadley KW, McConnell MJ. 2010. Glioblastoma cells negative for the anti-CD133 antibody AC133 express a truncated variant of the CD133 protein. Int J Mol Med. 25:883-888.
37. Pallini R, Ricci-Vitiani L, Banna GL, Signore M, Lombardi D, Todaro M, Stassi G, Martini M, Maira G, Larocca LM, et al. 2008. Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme. Clin Cancer Res. 14:8205-8212.
38. Platet N, Liu SY, Atifi ME, Oliver L, Vallette FM, Berger F, Wion D. 2007. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett. 258:286-290.
39. Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, De Maria R. 2007. Identification and expansion of human colon-cancer-initiating cells. Nature. 445:111-115.
40. Riquelme PA, Drapeau E, Doetsch F. 2008. Brain micro-ecologies: neural stem cell niches in the adult mammalian brain. Philos Trans R Soc Lond B Biol Sci. 363:123-137.
41. Sakariassen PO, Immervoll H, Chekenya M. 2007. Cancer stem cells as mediators of treatment resistance in brain tumors: status and controversies. Neoplasia. 9:882-892.
42. Scheres B. 2007. Stem-cell niches: nursery rhymes across kingdoms. Nat Rev Mol Cell Biol. 8:345-354.
43. Seigel GM, Campbell LM, Narayan M, Gonzalez-Fernandez F. 2005. Cancer stem cell characteristics in retinoblastoma. Mol Vis. 11:729-737.
44. Seigel GM, Hackam AS, Ganguly A, Mandell LM, Gonzalez- Fernandez F. 2007. Human embryonic and neuronal stem cell markers in retinoblastoma. Mol Vis. 13:823-832.
45. Shi SR, Liu C, Pootrakul L, Tang L, Young A, Chen R, Cote RJ, Taylor CR. 2008. Evaluation of the value of frozen tissue section used as gold standard for immunohistochemistry. Am J Clin Pathol. 129:358-366.
46. Shu Q, Wong KK, Su JM, Adesina AM, Yu LT, Tsang YT, Antalffy BC, Baxter P, Perlaky L, Yang J, et al. 2008. Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma. Stem Cells. 26:1414-1424.
47. Silverman JF, Jones FD, Unverferth M, Berns L. 1989. Cytopathology of neoplasms of the central nervous system in specimens obtained by the Cavitron Ultrasonic Surgical Aspirator. Acta Cytol. 33:576-582.
48. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. 2003. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821-5828.
49. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. 2004. Identification of human brain tumour initiating cells. Nature. 432:396-401.
50. Son MJ, Woolard K, Nam DH, Lee J, Fine HA. 2009. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 4:440-452.
51. Sulman EP, Goodman LD, Le TT, Pelloski CE, Bhat K, Gumin J, Lang FF, Colman H, Aldape KD. 2008. A novel marker of glioma stem cells that is prognostic for treatment response and patient outcome. Presented at the 99th Annual Meeting of the American Association for Cancer Research, April 12-16, San Diego, CA. Abstract 3777.
52. Thon N, Damianoff K, Hegermann J, Grau S, Krebs B, Schnell O, Tonn JC, Goldbrunner R. 2010. Presence of pluripotent CD133(+) cells correlates with malignancy of gliomas. Mol Cell Neurosci. 43:51-59.
53. Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A, Prestegarden L, Rosland G, Thorsen F, Stuhr L, et al. 2008. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer. 122:761-768.
54. Yin AH, Miraglia S, Zanjani ED, Meida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW. 1997. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood. 90:5002-5012.
55. Zeppernick F, Ahmadi R, Campos B, Dictus C, Helmke BM, Becker N, Lichter P, Unterberg A, Radlwimmer B, Herold- Mende CC. 2008. Stem cell marker CD133 affects clinical outcome in glioma patients. Clin Cancer Res. 14:123-129.
56. Zhang M, Song T, Yang L, Chen R, Wu L, Yang Z, Fang J. 2008. Nestin and CD133: valuable stem cell-specific markers for determining clinical outcome of glioma patients. J Exp Clin Cancer Res. 27:85.
57. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH, Nephew KP. 2008. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 68:4311-4320.
58. Zhu Y, Guignard F, Zhao D, Liu L, Burns DK, Mason RP, Messing A, Parada LF. 2005. Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell. 8:119-130.